ACTUS-101 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 256 | 筋型糖原病 | 1 |
256. 筋型糖原病
臨床試験数 : 180 / 薬物数 : 133 - (DrugBank : 29) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03533673 (ClinicalTrials.gov) | December 17, 2018 | 13/4/2018 | AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease | A Phase 1 Study of the Safety of AAV2/8-LSPhGAA (ACTUS-101) in Late-onset Pompe Disease | Pompe Disease | Biological: ACTUS-101 | Asklepios Biopharmaceutical, Inc. | NULL | Recruiting | 18 Years | N/A | All | 13 | Phase 1/Phase 2 | United States |